theory clinical_30_8
imports Main

begin

typedecl entity
typedecl event

consts
  Mutations :: "entity ⇒ bool"
  Activating :: "entity ⇒ bool"
  CTNNB1 :: "entity ⇒ bool"
  Proliferation :: "entity ⇒ bool"
  Cells :: "entity ⇒ bool"
  Promote :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  Via :: "entity ⇒ entity ⇒ bool"
  βCatenin :: "entity ⇒ bool"
  Inhibit :: "event ⇒ bool"
  Reduce :: "event ⇒ bool"
  Stop :: "event ⇒ bool"
  Cause :: "entity ⇒ entity ⇒ bool"
  Reduction :: "entity ⇒ bool"
  Cessation :: "entity ⇒ bool"
  CrucialStep :: "event ⇒ bool"
  Treat :: "event ⇒ bool"
  Address :: "event ⇒ bool"
  UnderlyingCause :: "entity ⇒ bool"
  Directly :: "event ⇒ bool"
  EffectiveTreatment :: "event ⇒ bool"
  Effectiveness :: "event ⇒ bool"
  Treatment :: "event ⇒ bool"
  Ability :: "event ⇒ bool"
  Target :: "event ⇒ bool"
  Pathway :: "entity ⇒ bool"
  Lead :: "entity ⇒ entity ⇒ bool"
  Contribute :: "event ⇒ bool"
  Success :: "entity ⇒ bool"
  Thereby :: "event ⇒ bool"
  Enhance :: "event ⇒ bool"
  Responsible :: "entity ⇒ entity ⇒ bool"
  Ensure :: "event ⇒ bool"
  Effective :: "entity ⇒ bool"

(* Explanation 1: Activating mutations of CTNNB1 promote the proliferation of cells via β-catenin. *)
axiomatization where
  explanation_1: "∃x y z e. Mutations x ∧ Activating x ∧ CTNNB1 x ∧ Proliferation y ∧ Cells z ∧ Promote e ∧ Agent e x ∧ Patient e y ∧ Via y z ∧ βCatenin z"

(* Explanation 2: Inhibiting β-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1, and this reduction or cessation is a crucial step in treating these mutations. *)
axiomatization where
  explanation_2_1: "(∃x y z e1 e2. Inhibit e1 ∧ βCatenin x ∧ Agent e1 x ∧ Proliferation y ∧ Cells z ∧ (Reduce e2 ∨ Stop e2) ∧ Agent e2 x ∧ Patient e2 y ∧ Cause y z ∧ Mutations z ∧ Activating z ∧ CTNNB1 z)"
axiomatization where
  explanation_2_2: "(∃x y e. Reduction x ∧ Cessation y ∧ CrucialStep e ∧ Treat e ∧ Mutations x)"

(* Explanation 3: Reducing or stopping the proliferation of cells through inhibiting β-catenin directly addresses the underlying cause of cell proliferation, making it an effective treatment for patients with activating CTNNB1 mutations. *)
axiomatization where
  explanation_3_1: "(∃x y z e1 e2. (Reduce e1 ∨ Stop e1) ∧ Proliferation x ∧ Cells y ∧ Inhibit e2 ∧ βCatenin z ∧ Agent e2 z ∧ Address e1 ∧ Cause x y ∧ UnderlyingCause y ∧ Directly e1)"
axiomatization where
  explanation_3_2: "(∃x y e. EffectiveTreatment e ∧ Patient e x ∧ Mutations x ∧ Activating x ∧ CTNNB1 x)"

(* Explanation 4: The effectiveness of inhibiting β-catenin as a treatment is due to its ability to target the specific pathway that leads to cell proliferation in patients with activating CTNNB1 mutations, thereby directly contributing to the treatment's success. *)
axiomatization where
  explanation_4_1: "(∃x y z e1 e2. Effectiveness e1 ∧ Inhibit e2 ∧ βCatenin x ∧ Treatment e1 ∧ Ability e2 ∧ Target e2 ∧ Pathway y ∧ Lead y z ∧ Proliferation z ∧ Cells z ∧ Patient e1 z ∧ Mutations z ∧ Activating z ∧ CTNNB1 z)"
axiomatization where
  explanation_4_2: "(∃x e. Contribute e ∧ Success x ∧ Treatment x ∧ Directly e ∧ Thereby e)"

(* Explanation 5: Inhibiting β-catenin not only reduces cell proliferation but also enhances the effectiveness of treatment for patients with activating CTNNB1 mutations by directly targeting the pathway responsible for cell proliferation, ensuring the treatment is effective. *)
axiomatization where
  explanation_5_1: "(∃x y z e1 e2 e3. Inhibit e1 ∧ βCatenin x ∧ Reduce e2 ∧ Proliferation y ∧ Cells y ∧ Enhance e3 ∧ Effectiveness z ∧ Treatment z ∧ Patient z y ∧ Mutations y ∧ Activating y ∧ CTNNB1 y)"
axiomatization where
  explanation_5_2: "(∃x y e. Target e ∧ Pathway x ∧ Responsible x y ∧ Proliferation y ∧ Cells y ∧ Directly e)"
axiomatization where
  explanation_5_3: "(∃x e. Ensure e ∧ Treatment x ∧ Effective x)"

theorem hypothesis:
  assumes asm: "βCatenin x ∧ Mutations y ∧ Activating y ∧ CTNNB1 y"
  (* Hypothesis: Inhibiting β-catenin may be effective in treating patients with activating CTNNB1 mutations *)
  shows "∃x y e1 e2. Inhibit e1 ∧ βCatenin x ∧ Agent e1 x ∧ Effective e2 ∧ Treat e2 ∧ Patient e2 y ∧ Mutations y ∧ Activating y ∧ CTNNB1 y"
proof -
  (* From the known information, we have βCatenin x, Mutations y, Activating y, and CTNNB1 y. *)
  from asm have "βCatenin x ∧ Mutations y ∧ Activating y ∧ CTNNB1 y" <ATP>
  
  (* Explanation 2 states that inhibiting β-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1. *)
  (* This reduction or cessation is a crucial step in treating these mutations. *)
  (* We have the logical relation Implies(D, E) and Implies(E, F), which means inhibiting β-catenin leads to treatment for activating CTNNB1 mutations. *)
  then have "∃e1. Inhibit e1 ∧ βCatenin x ∧ Agent e1 x ∧ Mutations y ∧ Activating y ∧ CTNNB1 y" <ATP>
  
  (* Explanation 4 and the logical relation Implies(D, G) indicate that inhibiting β-catenin leads to the effectiveness of treatment. *)
  (* Therefore, we can infer the effectiveness of the treatment. *)
  then have "∃e2. Effective e2 ∧ Treat e2 ∧ Patient e2 y ∧ Mutations y ∧ Activating y ∧ CTNNB1 y" <ATP>
  
  (* Combining the above steps, we can conclude the hypothesis. *)
  then show ?thesis <ATP>
qed

end
